NEW YORK (GenomeWeb News) – Sequenta has gained the exclusive rights to iRepertoire's IP related to methods of immune cell sequencing for minimal residual disease testing, the two companies said today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.